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Abstract 
Dysregulation of miRNAs can contribute to the aetiology of diseases including pulmonary arterial 
hypertension (PAH).  Here we investigated a potential role for the miR-214 stem loop miRNA and the 
closely linked miR-199a miRNAs in PAH. All 4 miRNAs were upregulated in the lung and right ventricle 
in mice and rats exposed to the SU 5416 hypoxia model of PAH. Further, expression of the miRNAs was 
increased in PASMCs exposed to TGF-β1 but not BMP4. We then examined miR-214-/- mice exposed to 
the SU 5416 hypoxia model of PAH or normoxic conditions and littermate controls. There were no 
changes in systolic right ventricular pressure or remodelling observed between the miR-214-/- and WT 
hypoxic groups. However, we observed a significant increase in right ventricular hypertrophy in hypoxic 
miR-214-/- male mice compared to controls. Further, we identified that the validated miR-214 target 
phosphatase and tensin homolog was upregulated in miR-214-/- mice. Thus, miR-214 stem loop loss leads 
to elevated right ventricular hypertrophy and may contribute to the heart failure associated with PAH. 
Key Words 
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Introduction 
Pulmonary arterial hypertension (PAH) is a disease characterized by narrowing of the small pulmonary 
arteries, leading to vascular remodelling, an elevation in pulmonary artery pressure, right ventricular 
hypertrophy (RVH) and heart failure.1 Current therapies for PAH aim to reverse the endothelial 
dysfunction and vasoconstriction observed. 2  However, despite these therapies PAH mortality rates 
remain high and the three-year survival of patients is only 54.9%. 3 
Changes in the pulmonary vasculature are the primary cause of PAH, however right ventricle (RV) 
function is a major determinant of the severity of symptoms and prognosis of pulmonary hypertension.  
Many therapies in development for PAH are focussed on targeting the RV as heart failure is the ultimate 
cause of mortality in PAH.4  PAH is predominant in females with female-to-male ratios of 1.4-4.1:1 
(reviewed in 5).  Sexual dimorphism has also been observed in RV failure. Female PAH patients exhibit 
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improved right ventricular ejection fraction and survival compared to men 6. This could be due at least in 
part to the protective effect of estrogen on RV function.7,8 
MiRNA are involved in multiple cellular responses during normal development and disease; they act as 
post-transcriptional regulators to fine-tune protein synthesis. Evidence has emerged for a key role for 
miRNA in regulation of the cellular processes involved in PAH.  We previously demonstrated that a 
range of miRNAs are dysregulated in rats exposed to models of PAH.9  Later studies have shown that 
miR–21, the miR–143/145 cluster, miR–27a, the miR–17–92 cluster, miR–124, miR-150, miR–138, 
miR–190, miR–204, miR–206, miR–210 and miR–328  play a role in the development of PAH (reviewed 
in 10). Potentially multiple miRNAs could be targeted in concert as therapeutics in PAH.11  
MiR-214 is transcribed as a bicistronic primary transcript, which is processed to generate four separate 
mature miRNAs, the main strands miR-199-5p and miR-214-3p and their passenger strands miR-199-3p 
and miR-214-5p. MiR-199-5p and miR-214-3p have previously been shown to be significantly 
upregulated at the mature miRNA level in both the hypoxia and moncrotaline rat models.9  In cardiac 
tissue, miR-214 is a marker of stress12 and expression increases in RVH, heart failure and ischemic injury 
in the heart.13-15 The role of miR-214 in the heart is controversial as one study suggests miR-214 is 
protective in ischaemia reperfusion injury,13 whereas another suggests miR-214 ablation is protective in 
heart failure.15.MiR-214 deletion leads to increased fibrosis, apoptosis and decreased contractility after 
ischemic injury in the heart, a result of target derepression of the sodium/calcium exchanger member 1 
(NCX1), leading to calcium over-loading of cardiomyocytes.13 However, inhibition of miR-199/214 using 
anti-miRs in mice is protective through target derepression of peroxisome proliferator-activated receptor 
delta (PPARδ) and restoration of mitochondrial fatty acid oxidation in the heart.15  
MiR-214 also has functions in tissues other than the heart. MiR-214 can inhibit angiogenesis through 
targeting the KH domain containing RNA binding (QKI) transcript in a retinal developmental 
angiogenesis model in mice. 16  MiR-214 can also function as both a tumour suppressor and oncogene in 
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various types of human cancer, through influencing proliferation, migration and apoptosis.17-20 Therefore, 
though its effects may be varied, miR-214 can influence processes important in PAH in a cell type 
specific manner. 
MiR-214 is induced by transforming growth factor beta 1 (TGF- β1)21 and is upregulated in kidney and 
liver fibrosis.21-24  Whilst in the heart miR-214 ablation depending on the injury can be protective or 
deleterious, in the kidney miR-214 knockout is protective against fibrosis.13  TGF- β1 is a critically 
important mediator of pathophysiological events in PAH and fibrosis.25-28  Many processes in PAH and 
fibrosis are known to be driven primarily by TGF- β1 along with a host of other cytokines and growth 
factors.28  It is probable that these processes involve complex and interrelated molecular pathways in 
which miRNA play an important role.  
As miR-214 is implicated in many of the processes associated with PAH pathology we characterised the 
miR-214 knockout (miR-214-/-) mouse. We used the hypoxia SU 5416 model to induce PAH and assessed 
the pathological hallmarks of disease. Despite observing no effect on vascular remodelling and RSVP in 
the miR-214-/- mice, we found a significant damaging effect on right ventricular hypertrophy in male but 
not in female miR-214-/- mice.   
Materials and Methods 
RNA extraction, miRNA and mRNA expression 
Total RNA from PASMCs was obtained using the miRNeasy kit (Qiagen, Hilden, Germany). cDNA for 
miRNA analysis was synthesised from total RNA using specific stem-loop reverse transcription primers 
(Life Technologies, Paisley, UK). mRNA/miRNA expression was assessed using specific primers by 
quantitative real-time polymerase chain reaction (qRT-PCR; Life Technologies) and normalised to a 
housekeeper.  For gene expression β-2-microglobulin (B2M) or glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) were used for mouse and human samples respectively. For miRNA control, the 
small RNA U6 (mouse) U87 (rat) or RNU48 (human) were used.  Results were expressed as fold change 
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relative to the relevant control. The qPCRs were run in triplicate and results are presented as the mean ± 
the standard error of samples.  MiR-214 target genes for analysis were selected on the basis of previous 
knowledge of validated target genes. 
Cell culture and stimulation  
Single donor hPASMCs were obtained from PromoCell (GmbH, Heidelberg, Germany).  Cells were used 
between passages 1 and 8.  PASMCs were grown to 80% confluency in 6 well plates, quiesced in DMEM 
with 0.2% FBS for 24 hours before being stimulated or placed in a hypoxic chamber (5% O, 5% CO2, 
90% N2) for 48 hours. The Smad signalling pathway was assessed by recombinant human TGF-β1 (0.1-
10ng/ml) BMP4 (50ng/ml R&D systems, Minneapolis, MN) and the commercially available ALK5-
specific inhibitor SB525334 (1nm, Tocris Bioscience, Bristol, UK).  Cells were quiesced in 0.2% FBS for 
24 hours, followed by stimulation for 72 hours and then the media was changed to fresh stimulation 
media for 48 hours (5 days stimulation in total). 
Disease Modelling In Vivo  
All protocols and surgical procedures were approved by the local animal care committee. Animal 
experiments were conducted in accordance with the Animals Scientific Procedures Act UK 1986. For the 
2 and 3 week hypoxia models the development of chronic hypoxic PAH in 8 week old C57BL/6 mice was 
achieved with hypobaric hypoxia as previously described.29   
MiR-214-/- and wild-type (WT) littermate control mice were used in this study (kindly gifted by Eric 
Olson, University of Texas Southwestern Medical Center 13). PAH was established in male and female 8 
week old miR-214 WT and knockout mice by serial injection (days 0, 7 and 14) with the vascular 
endothelial growth factor Flk-1/KDR receptor inhibitor Semaxanib (SU 5416, 20 mg/kg subcutaneously; 
Sigma Aldrich, Poole, UK) in combination with 21 days continuous exposure to hypoxia.   PAH was 
established in Wistar Kyoto rats by one injection (day 0) with SU 5416 (20 mg/kg subcutaneously) in 
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combination with 2 weeks continuous exposure to hypoxia, followed by 3 weeks in normoxic 
conditions30,31. 
Hemodynamic Measurements 
Right ventricular systolic and systemic pressure measurements were taken on day 21 prior to euthanasia, 
right ventricular hypertrophy assessment and tissue harvest.  Systemic arterial pressure (SAP) was 
recorded via a cannula placed in the carotid artery as previously described.29 Right ventricular systolic 
pressure (RVSP) was measured under isoflurane (1.5% O2) anaesthesia via a needle advanced into the 
right ventricle trans-diaphragmatically. RVH was determined as ratio of the RV to the left ventricle plus 
septum (LV + S) weight.  
Immunohistochemistry  
Lungs were fixed in a 4% paraformaldehyde solution for 18 hours and embedded in paraffin. For lung α-
smooth muscle actin immunohistochemistry anti-α-smooth muscle actin (1:100, Abcam, Cambridge, MA) 
and IgG-control were used for detection. For remodelling analysis distal vessels were assessed (≤80 
microns) a ratio of vascular wall thickness: vascular diameter was determined and used to define the 
extent of pulmonary vascular thickness and remodelling (10 distal pulmonary arteries were quantitatively 
analysed from 6 animals per group). 
For hematoxylin and eosin staining of right ventricle, sections were incubated with hematoxylin solution 
(Sigma-Aldrich, Poole, UK) for 5 minutes and then rinsed in water, washed in 95% alcohol and 
counterstained in eosin Y solution (Sigma-Aldrich).  For picrosirius red staining of right ventricle, 
sections were stained with Weigert’s hematoxylin and Solution B (Sigma-Aldrich) for 10 minutes at room 
temperature. Slides were washed and incubated in the dark with Sirius red F3B (0.1% w/v) (Sigma-
Aldrich) for 4 hours. 
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In situ hybridization  
Detection of miR-214 in lung and right ventricle tissue was carried out as previously described.32  In brief, 
after sodium citrate antigen retrieval and blocking (50% formamide, 4 x SSC, 2.5 x Denhardt’s solution, 
2.5mg/ml salmon DNA, 0.6mg/ml yeast tRNA, 0.025% SDS and 0.1% blocking reagent)  5μm sections  
were incubated in blocking buffer overnight with 40nM miR-214 or scramble miRCURY LNATM 
Detection probe, 3’ and 5’-DIG labelled (Exiqon, Denmark) at 60℃ . After stringency washing with SSC 
buffer and PBS and blocking (1% blocking reagent and 10% FCS in PBS), immunodetection was 
performed with an anti-DIG antibody (Roche Applied Science, Indianapolis, IN, USA) diluted 1:500 
overnight. In order to stain miR-214, BM purple solution (Roche Applied Science, Mannheim, Germany) 
was added to each section respectively and left at room temperature for 5 hours.  
Statistical analysis 
Prior to experimental analysis, power calculations were utilized to ensure appropriately powered 
experiments. All qRT-PCR results are expressed as mean fold change (±SEM) with all other results 
expressed as the mean (±SEM).  All statistical calculations were carried out using GraphPad Prism or 
Excel. Student’s t-tests were used when comparing two conditions and a two-way ANOVA with 
Bonferroni correction or 1-way ANOVA followed by Tukey post hoc test were used for multiple 
comparisons. Probability values of less than 0.05 were considered significant.   
Results 
miR-214 is induced by TGF-β1 in PASMCs 
The primary transcript of miR-214 (pri-miR-199/214) is located on chromosome 1 in humans and is 
transcribed together with miR-199, which is processed to generate 4 separate mature miRNAs (miR-214-
3p, miR-214-5p, miR-199-3p and miR-199-5p).  The transcriptional start site for human pri-miR-199/214 
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is at position chr1:172113935 (GRCh37).33  The locus contains an upstream region of ~2.4 kb with >60% 
homology to other mammalian species (ECR browser).34 
We first carried out in silico analysis of this putative promoter region using MatInspector (Genomatix 
software suite, http://www.genomatix.de). This revealed a number of putative binding sites for TGF-β1 
responsive transcription factors, including several binding sites for Smad proteins (Fig. 1A). We tested 
the effect of TGF-β1 treatment in PASMCs and analyzed changes in the miR-199/214 axis by RT-qPCR, 
by assessing the primary (pri-) and mature forms of each miRNA. TGF-β1 increased the expression of 
pri-miR-199/214 in PASMC (Fig. 1B).  Correspondingly, TGF-β1 increased the expression of the 4 
mature forms of the miR-199/214 cluster (Fig. 1C). Treatment of PASMC with a specific inhibitor of the 
TGF-β receptor ALK5, SB525334, completely abolished this effect (Fig. 1B and 1C). It has been shown 
previously that miR-214 is upregulated by hypoxia in cardiomyocytes,15 but we found that hypoxia and 
BMP4 treatment did not affect the basal levels of the mature miRNAs in the miR-199/214 cluster in 
PASMCs (Fig. 1D and 1E).  
Expression of the miR-199/214 axis in mouse and rat models of PAH 
TGF-β1 has an established role in PAH.21,27,28 Therefore, we investigated expression of the pri-miR-
199/214 transcript and mature miRNAs in mouse and rat models of PAH. 
We sampled total lung and the right ventricle from WT mice exposed to hypoxia and SU 5416 for 21 
days, or rats exposed to 14 days hypoxia and SU 5416 followed by 21 days normoxia.   This data was 
compared with normoxic controls to evaluate whether the miR-199/214 axis was altered during induction 
of PAH in these tissues.  Expression levels for both strands of miR-199 and miR-214 were analyzed by 
qRT-PCR. 
Levels of pri-miR-199/214 were upregulated in mouse lung and RV in response to hypoxia and SU 5416 
injury in both lung and RV (Fig. 2A).  Analysis of the miR-199/214 axis in the left ventricle of the same 
animals did not reveal dysregulation of this miRNA axis (Fig. 2B).  However, a significant upregulation 
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of the mature miRNAs in the miR-199/214 cluster was demonstrated in lung and RV both in mice and 
rats (Fig. 2C-F). We also observed a significant increase in expression of the miR-199/214 axis in lung 
and RV of mice exposed to 3 weeks hypoxia without SU 5416 (Fig. 3A and 3B). Further, the significant 
increase in miR-199/214 axis expression observed in males was not detected in female lung and RV 
exposed to 3 weeks hypoxia and SU 5416 injury (Fig. 3C and 3D). 
We next performed in situ hybridization to localize which cells were expressing miR-214 within the lung 
and RV of control rats exposed to hypoxic and normoxic conditions. We observed that miR-214 was 
expressed in cardiomyocytes in the RV (Fig. 3E) and in the smooth muscle layer of vessels and bronchi in 
the lungs (Fig. 3F).  
Quantification of PAH indices in WT and miR-214-/- male and female mice exposed to SU 5416  and 
normoxic or hypoxic conditions for 21 days. 
We compared haemodynamics in WT mice and miR-214-/- in response to 21 days SU 5416 and hypoxia 
treatment in male and female mice in parallel and compared to littermate controls (Fig. 4A). 
Quantification of right ventricular and systemic pressures was performed along with heart rate 
measurements.  
In response to hypoxia and SU 5416 RVSP and RVH were significantly increased in both male and 
female mice (Fig. 4B, 4C, 5A and 5B). However, we observed that the increase in RVH in the male miR-
214-/- mice was greater than that in the WT controls (Fig. 5A). However, no significant change was 
observed in females (Fig. 4B). 
Knockout animals exposed to hypoxia demonstrated RVSP values comparable to those of hypoxic WT 
animals in both male and female mice (Fig. 4C and 5B). Similarly, comparable results were observed in 
remodelling analysis (Fig. 5E and 5F). Further, no difference in heart rate or systemic pressure was 
observed between groups (Fig 4D, 4E, 5C and 5D). Therefore, our results show that miR-214 knockout 
has a significant effect on RVH in male mice, but other PAH indices were unaffected.  
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Analysis of fibrosis, hypertrophy and miR-214 targets in in vivo samples 
Previous studies have shown that fibrosis was increased in an ischemia reperfusion model in the heart but 
decreased in a model of kidney fibrosis in miR-214-/- mice.13,21,35  In order to assess whether a change in 
fibrosis was important in the RV phenotype observed we assessed expression of collagen, type I, alpha 1 
(COL1A1) and collagen, type 3, alpha 1 (COL3A1) in male RV.  We found no significant change in 
expression level between groups (Fig. 6A, 6B).  There was no change in fibrosis between the groups, as 
assessed by picrosirius red staining (Fig. 6C). We carried out expression analysis for myosin, heavy chain 
7, cardiac muscle, beta, (MYH7) and myosin, heavy chain 11 (MYH11), in order to add further evidence 
to our observation that RV/LV+S ratio was increased in miR-214-/- mice.  Mutations in these hypertrophy 
markers are associated with hypertrophic cardiomyopathy.36 Both of these are modulated in hypertrophy, 
MYH7 is upregulated while MYH11 is downregulated.37 We found that expression of MYH11 decreased 
while MYH7 increased in hypoxia. Furthermore, MYH7 and MYH11 levels were significantly different 
between the miR-214-/- group compared to the WT (Fig. 6D and 6E). These data were indicative of 
increased RVH in the miR-214-/- group.  Taken together these results suggested that the increased RVH in 
miR-214-/- mice was due to hypoxia and SU 5416 induced hypertrophy rather than fibrosis or pressure 
overload.  
Target gene analysis was performed for previously validated miR-214 targets on mRNA extracted from 
male right ventricle.  We found that expression of phosphatase and tensin homolog (PTEN), which has 
been shown to have a role in RVH 38 was increased in the RV of miR-214-/- mice (Fig. 7A). This panel 
included NCX1 which has been shown previously to cause fibrosis and apoptosis in the heart.13 No 
significant regulation was observed in hypoxia between the miR-214-/- and WT mice for NCX1 or any of 
the other targets (Fig. 7). However, we did observe that cAMP responsive element binding protein 1 
(CREB1) and apolipoprotein C-III (APOC3) had significantly  increased expression in the miR-214-/- 
normoxic group compared to the WT normoxic group (Fig. 7D and 7E).  
12 
 
Discussion 
We demonstrated upregulation of the miR-199/214 axis in response to TGF-β1 in vitro and in response to 
mouse and rat models of PAH in vivo. We observed differential effects of genetic ablation of miR-214 on 
the PAH phenotype between the heart and lung and this effect was sex specific.  The increased RVH in 
the miR-214-/- mice was not dependant on derepression of NCX1, which has previously been shown to 
increase fibrosis and apoptosis in the heart.13 However, PTEN which has been implicated in RVH38 was 
identified as a target in RV and may play an important role in RVH in our model.  This data demonstrates 
that miR-214 is regulated in response to PAH stimuli and acts in a tissue and sex specific manner. 
Coding sequences for miR-199 and miR-214 stem loops are highly conserved, and are separated by 
~7.2kb on murine and human chromosome 1. MiR-214-3p has previously been shown to regulate fibrosis, 
angiogenesis and proliferation, which are also regulated by TGF-β1.39  In agreement with previous reports 
we demonstrated that miR-214-3p was regulated by TGF-β1.21  Here, we established that TGF-β1 induced 
transcription of pri-miR-199/214 and expression of all four mature miRNAs.  We identified an increase in 
expression of the miR-199/214 axis in RV and lung from mice and rats exposed to the SU 4516 hypoxia 
model of PAH.  Therefore, stimuli that lead to PAH could induce expression of the miR-199/214 axis. 
We investigated the effect of miR-214-3p/5p loss in vivo, but potentially the whole miR-199/214 axis 
could be important in PAH, as these co-regulated miRNAs could have a protective role in PAH.  It has 
been shown previously that miR-199 can target HIF-1α leading to reduced endothelin-1 expression.40  It 
would be interesting to investigate if a miR-199 and miR-214 knock out mouse would have a more 
pronounced PAH phenotype. 
We performed studies that assessed chronic knock down of miR-214 using knockout male and female 
mice. The female miR-214-/- mice displayed high RVSP and RVH in hypoxia similar to WT hypoxic 
mice, whereas, the male miR-214-/- mice had increased RVH compared to the WT hypoxic group (Fig. 4 
and 5).  Therefore, although genetic knockdown of miR-214 in this setting had no significant effect on the 
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development of PAH under the experimental conditions tested in females, miR-214 knockdown in males 
could progress RVH. 
PAH is a condition with a sex bias at the clinical level.41  Clinical as well as experimental data show a 
significant difference between males and females in cardiovascular responses.1,5,7,8  Previous studies have 
shown different pathophysiology between male and female mice in transgenic mouse model.8,42,43  
Furthermore, male PAH patients have decreased RV function compared to females 6 and male rodents and 
swine develop more severe RVH when exposed to chronic hypoxia compared with females.42,44 These 
significant sex differences in adaptation to hypoxia may reflect the different sensitivity of males and 
females to oxygen deprivation and other stresses. 
The incidence of pulmonary arterial hypertension is greater in women and a role has been confirmed for 
estrogen in disease pathogenesis.45-47 Male but not female mice had increased expression of the miR-
199/214 axis in lung and RV in SU 4516 hypoxia induced PAH (Fig. 2C-D, 3C-D).  It has been 
demonstrated previously that estrogen can inhibit the expression of miR-214.48 Therefore, increased 
levels of estrogen in females may prevent the expression of miR-214 in response to induction of PAH.  
This upregulation of miR-214 in males may account for some of the differences observed between the 
male and female mice.  Potentially, the increase in miR-214 observed in males exposed to hypoxia may 
have a protective effect in the heart, miR-214 induction does not occur in females, hence female knockout 
mice may be more resilient to miR-214 ablation. Part of this may be due to the inverse correlation 
between miR-214 and estrogen levels.48  Hence, pathway redundancy in females may compensate for the 
fluctuations in miR-214 mediated by estrogen.   
It has been shown previously that miR-214-/- mice have increased fibrosis in the heart, a result of target 
derepression of the sodium/calcium exchanger NCX1, leading to calcium over-loading of 
cardiomyocytes.13  However, in our study we did not observe any change in expression levels of NCX1 or 
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fibrosis (Fig. 6A-C and 7B).  Our data suggests that miR-214-/- mice have increased RVH and reduced 
RV function due to worsening of hypoxia and SU 4516 induced RVH by targets such as PTEN.   
Our data taken together with previous work demonstrates that miR-214 has specific effects in PAH 
induced RVH compared to whole heart in heart failure/ischemia reperfusion injury.  MiR-214 can target 
alternate targets between different models of heart disease as NCX1 and PPARδ are not targeted by miR-
214 in RV from our PAH model but were found to be targets in whole heart in other studies 13,15. 
However, analysis of miR-214 target genes revealed derepression of PTEN in the RV of miR-214-/- male 
mice (Fig. 7A and 7G) but not in female mice (not shown).  Increased levels of PTEN have been 
demonstrated in RVH.38  PTEN has opposing effects on PAH in the lung vasculature and RVH.38,49  
Further, PTEN has also been shown to increase proliferation, migration and invasion; in addition it can 
cause apoptosis of PASMCs.20,50 Potentially, derepression of PTEN in the lung of miR214-/- mice may 
have initially induced increased remodelling but may have caused apoptosis in PASMCs in the 
remodelled vessels at later stages of the model. This may account for the effect observed on RVH but not 
on RVSP or remodelling.  Differential effects of PTEN in a tissue specific manner may allow miR-214 to 
mediate cell type specific effects in response to the same regulatory stimuli.  However, further targets will 
be important in this model and additional studies are warranted to fully explore the miR-214 targets.   
The current paradigm suggests that RVH is secondary and proportional to pulmonary remodelling, 
however it has been found that pulmonary vascular remodelling and RVH can be dissociated and are not 
always directly proportional in PAH.51 However, both increased pulmonary vascular resistance and 
hypoxia can affect RVH and hypoxia can have a direct effect on the heart.52,53 This study shows that in 
miR-214-/- mice the hypoxia SU 4516 mouse model can increase RVH non-proportionally relative to 
RVSP.  Pathways involved in the response of the heart to hypoxia may be modulated by miR-214, this 
could be due to the target PTEN which has been shown to modulate responses to hypoxia.54  
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This data has implications for therapeutics as at the stage of PAH diagnosis vascular remodelling has 
occurred and leads to increased pulmonary vascular resistance and hypoxia in the heart.  Currently, 
remodelling cannot be reversed, however the response of the RV to hypoxia could be targeted.   MiR-214 
targets that may be beneficial in the RV may not be in the pulmonary circulation; therefore specific 
delivery of miR-214 to the RV using adeno-associated virus vectors could be an option as a therapeutic 
strategy.   
Taken together, the results of this study demonstrate that the miR-199/214 axis is induced in PAH. 
Moreover, genetic deletion of the miR-214 stem loop increases the development of RVH induced by 
transient exposure to hypoxia and SU 4516 injury in male mice. However, genetic deletion of miR-214 
stem loop has no effect on PAH in female mice. These data suggest that PAH pathology in the lung 
vasculature and heart is mediated via distinct pathways and identifies another potential source of sex 
specific variation. 
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Figure Legends 
Figure 1  
The miR-199/214 axis is induced by TGF-β1 stimulation but not by BMP4 or hypoxia in PASMCs. 
SMAD sites are present in the pri-miR-199/214 promoter (A) these are indicated by triangles (SMAD 2, 
blue; SMAD3, green; SMAD 4, yellow; FAST1, red). (B) PASMCs were treated with TGF-β1 with or 
without the specific ALK5 inhibitor SB525334 for 5 days (n/3, duplicate). Pri-miR-199/214 expression 
was assessed by quantitative real-time polymerase chain reaction (RT-qPCR).  (C) MiRNA expression for 
miR-199-5p, miR-199-3p, miR-214-3p, miR-214-5p. TGF-β1 only stimulation data were analyzed using a 
1-way analysis of variance with Tukey post hoc test, significance relative to unstimulated control (& 
p<0.05).  Student’s T test was used to compare samples stimulated with SB525334 to the equivalent 
unstimulated sample (Relative to SB525334 unstimulated sample:  * p<0.05, Relative to control 
unstimulated with TGF-β1: & p<0.05).  PASMCs were quiesced in DMEM with 0.2% FBS for 24 hours 
and then treated with BMP4 (50ng/ml) for 5 days (D) or exposed to hypoxic conditions for 48 hours after 
quiescence (E). miRNA expression was assessed by RT-qPCR (n=3, duplicate).  Student’s T test was 
used for statistical analysis.   
Figure 2 
The miR-199/214 axis is induced in lung and RV but not in LV from mice exposed to the SU 5416 
hypoxia model of pulmonary hypertension. (A) Pri-miR199/214 was quantified in mouse lung and RV. 
(B) MiRNA expression was quantified by RT-qPCR in mouse LV exposed to the SU 5416 hypoxia (21 
day) model of pulmonary hypertension. MiRNA expression was quantified by RT-qPCR in mouse lung 
(C) mouse RV (D) rat lung (E) rat RV (F) exposed to the SU 5416 hypoxia models of pulmonary 
hypertension.  Student’s T test was used for statistical analysis (* p<0.05, ** p<0.01, mouse tissues n=6, 
rat tissues n=8). 
Figure 3  
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The miR-199/214 axis is induced in lung and RV in male mice exposed to 3 weeks hypoxia but not in 
female mice exposed to hypoxia and SU 5416 for 21 days.  MiRNA expression was quantified by RT-
qPCR in male mouse lung (A) mouse RV (B) exposed to the 3 week hypoxia model of pulmonary 
hypertension or female mouse lung (C) mouse RV (D) exposed to hypoxia and SU 5416 for 21 days.    
Student’s T test was used for statistical analysis (* p<0.05, ** p<0.01 n=6). In situ hybridization showing 
miR-214-3p localization in rat RV (E) and rat lung (F). Paraffin sections were rehydrated and incubated 
with an anti–miR-214-3p or scramble probe as negative control. For colocalisation, α-smooth muscle 
actin (αSMA) was detected in the same samples using an immunohistochemistry assay, with nonimmune 
isotype-IgG antibody as negative control. Hematoxylin and eosin (H&E) stain were used to identify 
cardiomyocytes. Images ×40 magnification, (n=5). 
Figure 4  
Quantification of PAH indices in miR-214-/- and WT female mice exposed to SU 5416  and hypoxic or 
normoxic conditions for 21 days. (A) miR-214-/- and wild-type (WT) littermate mice were exposed to SU 
5416 plus 21-day chronic hypoxia or normoxia. Quantification of right ventricular hypertrophy (RVH; B), 
systolic right ventricular pressure (RVSP; C) systemic pressure (SAP; D) and heart rate (E) in female 
mice (n=8-10 per group). Pressures and tissue were taken after 21 days in normoxic or hypoxic 
conditions. Data analyzed using a 2-way ANOVA followed by Bonferroni post hoc test, * p<0.05, 
significance is expressed relative to WT normoxic. LV+S: left ventricle and septum; RV: right ventricle. 
Figure 5 
Quantification of PAH indices in miR-214-/- and WT male mice exposed to SU 5416  and hypoxic or 
normoxic conditions for 21 days. Quantification of right ventricular hypertrophy (RVH; A), systolic right 
ventricular pressure (RVSP;B) systemic pressure (SAP; C) and heart rate (D) in male mice (n=8-10 per 
group). Pressures and tissue were taken after 21 days in normoxic or hypoxic conditions. Pulmonary 
arterial remodelling quantification (E; n=6 per group) and representative pictures stained with smooth 
muscle actin (F), magnification ×40.  Data were analyzed using a 2-way ANOVA followed by Bonferroni 
post hoc test *P<0.05, significance is expressed relative to WT normoxic unless comparison is shown.  
LV+S: left ventricle and septum; RV: right ventricle. 
Figure 6 
Analysis of fibrosis and hypertrophy in male miR-214-/- and WT RV. Gene expression is assessed in 
mouse RV using specific probes and normalised to housekeeper (B2M).  COL1A1 (A) and COL3A1 (B) 
expression levels were quantified in miR-214-/- and WT RV exposed to normoxic or hypoxic conditions. 
Fibrosis was measured using picrosirius red staining, magnification ×40 (n=5) (C).  Expression levels of 
hypertrophy markers MYH11 (D) and MYH7 (E).  Data were analyzed using a 2-way ANOVA followed 
by Bonferroni post hoc test relative to WT normoxic unless comparison is shown. * p<0.05 (n=6). LV: 
left ventricle, RV: right ventricle, WT: wild-type, KO: miR214-/-. 
Figure 7 
Target gene analysis of miR-214-/- mice and the effect of miR-214 on RV and LV in hearts with different 
types of injury.  Target gene expression in male RV by quantitative real-time polymerase chain reaction 
for PTEN (A), NCX1 (B), PPARδ (C), CREB (D), APOC3 (E) and CAMK2D (F). Data were analyzed 
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using a 2-way ANOVA followed by Bonferroni post hoc test, significance is expressed relative to WT 
normoxic unless comparison is shown,* p<0.05 (n=6).  MiR-214 can target alternate targets between 
different models of heart disease. PTEN, PPARδ and NCX1 are the targets identified in PAH RVH, heart 
failure and ischemia reperfusion injury respectively. 
